Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of ...

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors ...

Researchers have harnessed synthetic biology to engineer chimeric antigen receptor (CAR) T cells that precisely target and destroy cancer. However, these powerful cells can also attack healthy tissues ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

The Seattle Hub for Synthetic Biology is receiving a $10 million grant to support the training of new scientists and the ...

By leveraging our expertise in γδ T cell biology, we have worked to develop a breakthrough technology that combines exceptional preclinical potency, while broadly expanding immune surveillance ...

Peripheral T-cell lymphomas are a rare and heterogeneous type of lymphoma, with geographical and ethnic variations in histological subtypes that differ across the world.1 In The Lancet Haematology, ...